Sign In

Amy Finan

CEO, Sabin Vaccine Institute

Amy Finan is the Chief Executive Officer of the Sabin Vaccine Institute, a position she has held since April 2016.1 As CEO, she has led the development and implementation of a new organizational strategy focused on making vaccines more accessible, enabling innovation, and expanding immunization globally.1

Career Highlights

Under Finan's leadership, Sabin has achieved several notable accomplishments:

  • Launched a new R&D program in 2019, securing a license from GSK to develop vaccines against Ebola Sudan and Marburg viruses1
  • Rebuilt Sabin's immunization programs and strengthened relationships with global organizations like WHO, Gavi, UNICEF, and the Bill & Melinda Gates Foundation1
  • Expanded disease surveillance programs to aid countries in vaccine introduction decisions1
  • Implemented educational programs for journalists to report accurately on vaccines1

Previous Experience

Before joining Sabin, Finan's career included:

  • Senior Vice President at the Biotechnology Innovation Organization (BIO) for 11 years1
  • President of the Biotechnology Institute1
  • Corporate communications and investor relations lead at EntreMed, Inc.1
  • Director of government relations at the National Association for Biomedical Research1

Education and Personal

Amy Finan studied at the London School of Economics & Political Science and graduated with a bachelor's degree in political science from Trinity College in Washington, D.C.1 A native of Columbus, Ohio, she has lived in the Washington, D.C. area for over 35 years and currently resides in Bethesda, Maryland, with her family.1

Recent Activities

Finan has been actively involved in Sabin's efforts to combat infectious diseases:

  • She recently visited Rwanda's Marburg Command Post, supporting the country's efforts to manage the Marburg virus outbreak2
  • Under her leadership, Sabin delivered over 1,700 doses of the Marburg virus vaccine to protect frontline health workers in Rwanda2

Amy Finan continues to lead Sabin Vaccine Institute in its mission to make vaccines more accessible and expand immunization across the globe.13

Highlights

Apr 19 · linkedin

Last night, I had the privilege of being in the presence of individuals whose scientific brilliance is matched only by their unwavering dedication to the less fortunate. It takes a special sort of person to give up the course of comfort and embark on that rockier journey, dedicating much of their lives and careers to making life-saving vaccinations accessible in under-resourced countries.   For over 30 years, the Albert B. Sabin Gold Medal has been a beacon of scientific excellence and a testament to the transformative power of vaccines. The award recognizes the outstanding contributions of vaccinologists to the global health arena. Every Gold Medal Recipient has embodied Dr. Sabin’s abiding belief that immunization is as much about equity and health justice as it is about science.   We saw that same ethos sparkle brightly last night as we celebrated 2024 recipients Dr. Keith Klugman and Dr. Shabir Madhi at our annual Gold Medal and Rising Star ceremony at the National Academy of Sciences in Washington D.C. Keith and Shabir are South African physician-scientists whose contributions to vaccines for pneumonia and diarrheal diseases have saved more than 3.5 million lives in recent decades. Their research has helped pave the way for the introduction of pivotal vaccines in immunization programs – including the pneumococcal conjugate vaccine, where their findings significantly influenced vaccination policy in the Global South.    In recent years, vaccines have become increasingly politicized and pulled into a maelstrom of misinformation and disinformation. While the pandemic shone a spotlight on the power of vaccines, it has also underlined the issue of vaccine hesitancy which remains a global health threat. No country is exempt from this: here we are again in the United States with a measles resurgence right on our doorstep. Many have forgotten what it is to have lost lives and livelihoods from diseases because of #vaccines, a victim of its unparalleled ability to prevent disease and save lives.    Our 2024 Rising Star Prof. Nicole E. Basta gives me terrific hope as her research focuses on identifying new evidence to improve vaccination uptake and overall health in communities. The Rising Star award honors an emerging vaccine leader with a demonstrated commitment to the field of immunization. Nicole is all that and more. A first-generation college graduate, Nicole is now mentoring the next cohort of public health researchers through her teaching and research lab.   Each year at the close of this ceremony, I come away feeling optimistic and energized by those I meet from around the world, with renewed belief in Sabin's delivery model which centers on investing in local partners and codesigning approaches with stakeholders on the ground -- so that they are applicable to a community context with the highest chance of adoption.#vaccineswork

More on our 2024 Awardees: https://bit.ly/3xQ9yqO Wits Faculty of Health Sciences Bill & Melinda Gates Foundation

Oct 19 · linkedin

I have exciting news to share. Today, Sabin kicked off a Phase 2 clinical trial for our #Marburg vaccine candidate. The end goal: To protect communities against this lethal disease and avert the next Marburg outbreak. For a small-sized nonprofit like Sabin, this is a giant step forward. I am grateful for the many who helped get us here: the unstoppable perseverance and persistence of our R&D team who pulled many long nights to make this possible; our funders Biomedical Advanced Research and Development Authority (BARDA); our manufacturing partner REITHERA, our past and current colleagues at the The National Institutes of Health Vaccine Research Center and GSK, and the list goes on. Now, Sabin’s principal investigators, Dr. Betty Mwesigwa at Makerere University Walter Reed Project, and Dr. Nduba Videlis at the Kenya Medical Research Institute have joined the team to head up our Phase 2 trial with sites in Kampala, Uganda and Siaya, Kenya, respectively.   All these collaborative efforts came to fruition this morning when Dr. Mwesigwa’s team administered the Sabin Marburg vaccine to the first healthy adult participants in Uganda, a country familiar with the death and illness unleashed by Marburg. Dr. Nduba’s team in Kenya will start enrolling volunteers in the coming months. In 2024, we plan to conduct a similar Phase 2 clinical trial in the United States.   There are currently no approved vaccines for Marburg -- or for Sudan ebolavirus which is the other filovirus vaccine candidate that we are readying for a Phase 2 clinical trial. These viruses strike hard and are doing so with increased frequency, especially in the African continent – on average, one of every two individuals sickened by Marburg and Sudan #ebolavirus diseases succumbs to it.   As we learned from COVID-19, pandemics are inherently unpredictable. An uncontained outbreak in one remote place can rapidly become a global conflagration. Vaccines such as this one for Marburg are essential to get ahead of such a crisis.

Read more in our news release:

Related Questions

What are some of the key achievements of Amy Finan during her tenure at the Sabin Vaccine Institute?
How has Amy Finan's leadership impacted the global immunization efforts?
What strategies has Amy Finan implemented to make vaccines more accessible?
Can you provide more details about the new R&D program launched by Sabin under Amy Finan's leadership?
How has Amy Finan's background in political science influenced her approach to vaccine development?
Amy Finan
Amy Finan, photo 1
Amy Finan, photo 2
Add to my network

Location

Washington DC-Baltimore Area